XW033L7
Introduction Peripheral Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 3 Peripheral Vein |
| Approach | 3 Percutaneous |
| Device | L Lifileucel Immunotherapy |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Peripheral Vein
Peripheral veins are the superficial and deep venous vessels of the extremities and other non-central locations, commonly accessed for intravenous therapy because they are relatively easy to cannulate and carry lower procedural risk than central venous access. Introduction procedures coded here under New Technology involve infusing a novel substance through a peripheral vein into the systemic circulation, distinguishing this route from central venous administration where drug concentration, infusion rate, or vessel size requirements differ. Because peripheral veins have smaller caliber and lower flow rates than central vessels, certain New Technology agents may be formulated or dosed specifically for this route to minimize irritation or infiltration. Accurate coding depends on confirming that the access point was genuinely a peripheral rather than a central vein.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Lifileucel Immunotherapy
Lifileucel is an autologous tumor-infiltrating lymphocyte immunotherapy manufactured by harvesting T cells directly from a patient's own tumor tissue, expanding them ex vivo, and reinfusing them to attack the cancer, used in advanced melanoma. Unlike CAR T-cell products, it uses naturally tumor-reactive T cells without genetic engineering of a receptor, placing it in the non-CAR immune effector cell therapy category alongside agents like tabelecleucel.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.